Haemonetics Corporation

Equities

HAE

US4050241003

Medical Equipment, Supplies & Distribution

Market Closed - Nyse Other stock markets 01:30:02 15/06/2024 am IST			5-day change	1st Jan Change
84.66 ^USD	-1.62%		-1.11%	-0.99%

12/06	Haemonetics Shares Rise After Upgrade From Needham	MT
12/06	Needham Upgrades Haemonetics to Buy From Hold, Sets Price Target at $112	MT

Haemonetics Corporation Signs Multi-Year Supply Agreement with HemeXcel Purchasing Alliance LLC

January 13, 2014 at 02:30 am IST

Haemonetics Corporation announced that it has entered into a multi-year agreement to supply the HemeXcel Purchasing Alliance LLC with certain whole blood collection components on an exclusive basis during calendar years 2014-2016.

Latest news about Haemonetics Corporation

Haemonetics Shares Rise After Upgrade From Needham	13/06	MT
Needham Upgrades Haemonetics to Buy From Hold, Sets Price Target at $112	12/06	MT
Haemonetics Insider Sold Shares Worth $1,144,208, According to a Recent SEC Filing	30/05	MT
Haemonetics Insider Sold Shares Worth $775,253, According to a Recent SEC Filing	30/05	MT
Haemonetics Prices Upsized Private Placement of $600 Million Convertible Senior Notes	23/05	MT
Haemonetics Insider Sold Shares Worth $254,443, According to a Recent SEC Filing	22/05	MT
Haemonetics Plans Notes Offering	22/05	MT
Barrington Research Raises Price Target on Haemonetics to $107 From $105, Keeps Outperform Rating	10/05	MT
Haemonetics Seeks Acquisitions	09/05	CI
Transcript : Haemonetics Corporation, Q4 2024 Earnings Call, May 09, 2024	09/05
Haemonetics' Fiscal Q4 Adjusted Earnings, Revenue Rise	09/05	MT
Haemonetics Corporation Reports Earnings Results for the Full Year Ended March 30, 2024	09/05	CI
Haemonetics Corporation Reports Earnings Results for the Fourth Quarter Ended March 30, 2024	09/05	CI
Haemonetics Corporation Provides Revenue Guidance for the Fiscal Year 2025	09/05	CI
Haemonetics Gets FDA Clearance for New TEG 6s Global Hemostasis-HN Cartridge	04/04	MT
Haemonetics Corporation Receives FDA Clearance for New TEG®? 6s Global Hemostasis - HN Cartridge	04/04	CI
Haemonetics Corporation completed the acquisition of Advanced Cooling Therapy, Inc.	01/04	CI
Haemonetics to Acquire Attune Medical for $160 Million	05/03	MT
Haemonetics Corporation entered into a definitive agreement to acquire Advanced Cooling Therapy, Inc. for approximately $160 million.	05/03	CI
Haemonetics Q3 Adjusted Earnings, Revenue Increase; Shares Rise	08/02	MT
Transcript : Haemonetics Corporation, Q3 2024 Earnings Call, Feb 08, 2024	08/02
North American Morning Briefing : S&P 500 to Open -2-	08/02	DJ
Haemonetics Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended December 30, 2023	08/02	CI
Haemonetics Corporation Updates Revenue Guidance for the Fiscal Year 2024	08/02	CI
Transcript : Haemonetics Corporation Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-09-2024 09:45 AM	09/01

Chart Haemonetics Corporation

Duration

Period

More charts

Company Profile

Haemonetics Corporation is a global healthcare company. The Company is engaged in providing a suite of medical products and solutions for customers, to help them improve patient care and reduce the cost of healthcare. Its technology addresses various medical markets, including blood and plasma component collection, the surgical suite, and hospital transfusion services. The Companyâs Plasma segment includes plasma collection devices and disposables, donor management software and supporting software solutions sold to plasma customers. Its Blood Center segment includes blood collection and processing devices and disposables for red cells, platelets and whole blood. The Companyâs Hospital segment consists of Interventional Technologies, which includes vascular closure devices and sensor-guided technologies, and Blood Management Technologies, which includes devices and methodologies for measuring coagulation characteristics of blood, and blood transfusion management software, among others.

Sector

Medical Equipment, Supplies & Distribution

Calendar

06/08/2024 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Haemonetics Corporation

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

84.66 USD

Average target price

113.3 USD

Spread / Average Target

+33.81%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
HAEMONETICS CORPORATION	-0.99%	4.31B
ABBOTT LABORATORIES	-5.81%	180B
MEDTRONIC PLC	-1.63%	106B
BECTON, DICKINSON AND COMPANY	-4.14%	67.55B
DEXCOM, INC.	-6.56%	46.11B
CENCORA, INC.	+13.22%	45.79B
HOYA CORPORATION	+6.13%	41.61B
METTLER-TOLEDO INTERNATIONAL, INC.	+19.93%	31.07B
TERUMO CORPORATION	+13.61%	24.77B
WEST PHARMACEUTICAL SERVICES, INC.	-5.36%	24.27B

Other Medical Equipment, Supplies & Distribution